6-叔-丁基二甲基硅烷基-4’-羟基雷洛昔芬 | 174264-47-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 6-叔-丁基二甲基硅烷基-4’-羟基雷洛昔芬
• 英文名称: (6-((tert-butyldimethylsilyl)oxy)-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone
• 英文别名: (6-(tert-butyldimethylsilyloxy)-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone；6-tert-Butyldimethylsilyl-4'-hydroxy Raloxifene；[6-[tert-butyl(dimethyl)silyl]oxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone
• CAS: 174264-47-2
• 化学式: C₃₄H₄₁NO₄SSi
• 分子量: 587.855
• InChiKey: LVZAJJMYYKOTDQ-UHFFFAOYSA-N

物化性质

• 熔点：
  98-100°C
• 沸点：
  706.2±60.0 °C(Predicted)
• 密度：
  1.149±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于丙酮、氯仿、二氯甲烷、乙醇、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  8.75
• 重原子数：
  41
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  87.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  6-叔-丁基二甲基硅烷基-4’-羟基雷洛昔芬 在 palladium diacetate 、 1,3-双(二苯基膦)丙烷 、 三乙胺 作用下， 以 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 [6-[Tert-butyl(dimethyl)silyl]oxy-2-(4-ethenylphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone
  参考文献：
  名称：

  Structure−Activity Relationships of Selective Estrogen Receptor Modulators:  Modifications to the 2-Arylbenzothiophene Core of Raloxifene

  摘要：

  The 8-arylbenzothiophene raloxifene, 1, is a selective estrogen receptor modulator which is currently under clinical evaluation for the prevention and treatment of postmenopausal osteoporosis. A series of raloxifene analogs which contain modifications to the 2-arylbenzothiophene core have been prepared and evaluated for the ability to bind to the estrogen receptor and inhibit MCF-7 breast cancer cell proliferation in vitro. Their ability to function as tissue-selective estrogen agonists in vivo has been assayed in a short-term, ovariectomized (OVX) rat model with end points of serum cholesterol lowering, uterine weight gain, and uterine eosinophil peroxidase activity. These studies have demonstrated that (1) the 6-hydroxy and, to a lesser extent, the 4'-hydroxy substituents of raloxifene are important for receptor binding and in vitro activity, (2) small, highly electronegative 4'-substituents such as hydroxy, fluoro, and chloro are preferred both in vitro and in vivo, (3) increased steric bulk at the 4'-position leads to increased uterine stimulation in, vivo, and (4) additional substitution of the 2-aryl moiety is tolerated while additional substitution at the 4-, 5-, or 7-position of the benzothiophene results in reduced biological activity. In addition, compounds in which the 2-aryl group is replaced by alkyl, cycloalkyl, and naphthyl substituents maintain a profile of in vitro and in vivo biological activity qualitatively similar to that of raloxifene. Several novel structural variants including 2-cyclohexyl, 2-naphthyl, and 6-carbomethoxy analogs also demonstrated efficacy in preventing bone loss in a chronic OVX rat model of postmenopausal osteopenia, at doses of 0.1-10 mg/kg.

  DOI：

  10.1021/jm9606352
• 作为产物：
  描述：

  叔丁基二甲基氯硅烷 、 盐酸雷洛昔芬 在 4-二甲氨基吡啶 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 以12%的产率得到6-叔-丁基二甲基硅烷基-4’-羟基雷洛昔芬
  参考文献：
  名称：

  [EN] LYMPH DIRECTING PRODRUGS
  [FR] PROMÉDICAMENTS DE TRANSPORT VERS LE SYSTÈME LYMPHATIQUE

  摘要：

  这项发明涉及化合物及其用途，特别是以前药物形式存在的促进药物运输至淋巴系统并随后增强母药释放的前药化合物。

  公开号：

  WO2016023082A1

文献信息

• Versatile raloxifene triflates
  作者：Michael J. Martin、Timothy A. Grese、Andrew L. Glasebrook、Ken Matsumoto、Lewis D. Pennington、D.Lynn Phillips、Lorri L. Short

  DOI：10.1016/s0960-894x(97)00130-3

  日期：1997.1

  Methodology has been employed that permits the differentiation of the phenols of raloxifene. Transition metal mediated transformations of raloxifene triflates have subsequently provided a number of analogs that were evaluated further in two in vitro models predictive of estrogen receptor mediated biological activity. (C) 1997 Elsevier Science Ltd.
• Synthesis and estrogen receptor binding affinities of the major human metabolites of raloxifene (LY139481)
  作者：Jeffrey A. Dodge、Charles W. Lugar、Stephen Cho、John J. Osborne、David L. Phillips、Andrew L. Glasebrook、Charles A. Frolik

  DOI：10.1016/s0960-894x(97)00142-x

  日期：1997.4

  Glucuronide conjugates 1 and 2, the major metabolites of raloxifene, have been prepared and their molecular interactions with the estrogen receptor determined. (C) 1997 Elsevier Science Ltd.
• [EN] LYMPH DIRECTING PRODRUGS<br/>[FR] PROMÉDICAMENTS DE TRANSPORT VERS LE SYSTÈME LYMPHATIQUE
  申请人：UNIV MONASH

  公开号：WO2016023082A1

  公开（公告）日：2016-02-18

  H:\dar\Interwoven\NRPortbl\DCC\DAR\8230712_1.doc-12/08/2015 Abstract The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.

  这项发明涉及化合物及其用途，特别是以前药物形式存在的促进药物运输至淋巴系统并随后增强母药释放的前药化合物。
• Structure−Activity Relationships of Selective Estrogen Receptor Modulators:  Modifications to the 2-Arylbenzothiophene Core of Raloxifene
  作者：Timothy A. Grese、Stephen Cho、Don R. Finley、Alexander G. Godfrey、Charles D. Jones、Charles W. Lugar、Michael J. Martin、Ken Matsumoto、Lewis D. Pennington、Mark A. Winter、M. Dee Adrian、Harlan W. Cole、David E. Magee、D. Lynn Phillips、Ellen R. Rowley、Lorri L. Short、Andrew L. Glasebrook、Henry U. Bryant

  DOI：10.1021/jm9606352

  日期：1997.1.1

  The 8-arylbenzothiophene raloxifene, 1, is a selective estrogen receptor modulator which is currently under clinical evaluation for the prevention and treatment of postmenopausal osteoporosis. A series of raloxifene analogs which contain modifications to the 2-arylbenzothiophene core have been prepared and evaluated for the ability to bind to the estrogen receptor and inhibit MCF-7 breast cancer cell proliferation in vitro. Their ability to function as tissue-selective estrogen agonists in vivo has been assayed in a short-term, ovariectomized (OVX) rat model with end points of serum cholesterol lowering, uterine weight gain, and uterine eosinophil peroxidase activity. These studies have demonstrated that (1) the 6-hydroxy and, to a lesser extent, the 4'-hydroxy substituents of raloxifene are important for receptor binding and in vitro activity, (2) small, highly electronegative 4'-substituents such as hydroxy, fluoro, and chloro are preferred both in vitro and in vivo, (3) increased steric bulk at the 4'-position leads to increased uterine stimulation in, vivo, and (4) additional substitution of the 2-aryl moiety is tolerated while additional substitution at the 4-, 5-, or 7-position of the benzothiophene results in reduced biological activity. In addition, compounds in which the 2-aryl group is replaced by alkyl, cycloalkyl, and naphthyl substituents maintain a profile of in vitro and in vivo biological activity qualitatively similar to that of raloxifene. Several novel structural variants including 2-cyclohexyl, 2-naphthyl, and 6-carbomethoxy analogs also demonstrated efficacy in preventing bone loss in a chronic OVX rat model of postmenopausal osteopenia, at doses of 0.1-10 mg/kg.